A-PLUS
A-PLUS
Avasimibe & Progression of Coronary Lesions Assessed by Intravascular UltraSound. A clinical trial using intravascular ultrasound (IVUS) as a primary end point, assessing the effects of an acyl-coenzyme A:cholesterol acetyltransferase (ACAT) inhibitor, avasimibe, on progression of atherosclerosis.Conclusion Diagnostic IVUS imaging does not accelerate atherosclerosis in native human coronary arteries and can be used safely to assess disease progression/regression in clinical trials.